Search research articles
Contact Us
Filters
Showing results (701-710 of 742) with videos related to
Page
of 75
Sort By:
The New England Journal of Medicine
|
September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancer
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery
|
May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
The Lancet. Oncology
|
September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
Biorxiv : the Preprint Server for Biology
|
December 11, 2023
A (Sub)field Guide to Quality Control in Hippocampal Subfield Segmentation on Highresolution T<sub>2</sub>-weighted MRI
K L Canada, N Mazloum-Farzaghi, G Rådman, et al.
Science (New York, N.Y.)
|
November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
NPJ Precision Oncology
|
June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
Christopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
The Lancet. Oncology
|
September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Cancer Discovery
|
April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Page
of 75
Search research articles
Search
Showing results (701-710 of 742) with videos related to
Sort By:
Page
of 75
The New England Journal of Medicine
|
September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancer
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery
|
May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
The Lancet. Oncology
|
September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
Biorxiv : the Preprint Server for Biology
|
December 11, 2023
A (Sub)field Guide to Quality Control in Hippocampal Subfield Segmentation on Highresolution T<sub>2</sub>-weighted MRI
K L Canada, N Mazloum-Farzaghi, G Rådman, et al.
Science (New York, N.Y.)
|
November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
NPJ Precision Oncology
|
June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
Christopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
The Lancet. Oncology
|
September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Cancer Discovery
|
April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Page
of 75